Viral Vitalism

Source Library

Wegovy prescribing information

U.S. Food and Drug Administration is tracked in the Viral Vitalism canonical source library.

Regulatory labelU.S. health regulator
Source type
Regulatory label
Access type
Official
Publisher
U.S. Food and Drug Administration
Added
2026-06-19
Open original ->Source index

Trust profile

94

U.S. health regulator

Publisher type
Regulator
Bias profile
Low

Best used for

  • Approvals
  • Labels
  • Safety communications

Weak for

  • Comparative effectiveness
  • Consumer experience

Used in Viral Vitalism

Claims supported

  • GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level tolerability considerations.
  • Gallbladder events, pancreatitis warnings, kidney injury risk, hypoglycemia with certain concomitant drugs, and contraindication context matter in GLP-1 treatment decisions.
  • FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
  • Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.

Related studies

No structured study record is currently attached to this source.

Related sources

Topic tags

glp-1semaglutidewegovysafetylabel

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.